Teza Capital Management LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Teza Capital Management LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,917 shares of the biopharmaceutical company's stock, valued at approximately $437,000.

Several other institutional investors have also bought and sold shares of CPRX. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $27,000. Farther Finance Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after buying an additional 1,495 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $65,000. KBC Group NV grew its holdings in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after buying an additional 1,542 shares in the last quarter. Finally, Quarry LP bought a new stake in Catalyst Pharmaceuticals during the fourth quarter worth $104,000. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Trading Up 1.6%

Shares of CPRX stock traded up $0.38 on Friday, hitting $24.49. 772,723 shares of the stock were exchanged, compared to its average volume of 1,106,163. The firm has a market capitalization of $2.99 billion, a PE ratio of 20.75, a P/E/G ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The firm's 50 day moving average is $23.53 and its two-hundred day moving average is $22.56.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CPRX shares. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens restated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $32.29.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,000 shares of the stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,627,468.99. This represents a 38.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. The trade was a 25.04% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 351,879 shares of company stock worth $8,214,815. 10.40% of the stock is owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.